AbbVie Signs a Worldwide License Agreement with Jacobio to Advance SHP2 Inhibitors

 AbbVie Signs a Worldwide License Agreement with Jacobio to Advance SHP2 Inhibitors

AbbVie Signs a Worldwide License Agreement with Jacobio to Advance SHP2 Inhibitors

Shots:

  • AbbVie to get an exclusive global license to develop and commercialize JAB-3068 and JAB-3312 from Jacobio
  • AbbVie will provide undisclosed R&D cost to Jacobio for conducting early global CTs of JAB-3068 and JAB-3312. In addition, Jacobio has an exclusive option before registration trial initiation to develop and commercialize the SHP2 program in mainland China, Hong Kong, and Macau
  • JAB-3068 and JAB-3312, are oral small molecules to inhibit SHP2 activity, a protein mediator of cellular signaling through RAS/MAP kinase pathway for the treatment of cancer

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: AbbVie

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post